Diagnostic Utility of BCA-225 in Detecting Adenocarcinoma in Serous Effusions.
OBJECTIVE: To determine the diagnostic value of the BCA-225 antibody in discriminating adenocarcinoma from benign mesothelium in body cavity effusions.
STUDY DESIGN: One hundred four cases of unequivocally benign (34 cases) and malignant (70 cases) serous effusions with cell block material were immunostained for BCA-225 using the ABC method without antigen retrieval. The percentage of positively staining cells in each case was estimated in a blind fashion.
RESULTS: BCA-225 stained at least 10% of morphologically malignant cells in 28 of 32 (88%) breast carcinomas and 58 of 67 (87%) adenocarcinomas overall. Neuroendocrine carcinomas (two cases) and one mesothelioma were positive in < or = 5% of their respective tumor cells. Of 34 benign cases, 6 (18%) exhibited positive staining, albeit in rare, morphologically benign cells.
CONCLUSION: BCA-225 is able to discriminate adenocarcinoma from reactive mesothelium in cell block preparations and may prove useful as part of an antibody panel.
Published In/Presented At
Zimmerman, R. L., Fogt, F., & Goonewardene, S.A. (2000). Diagnostic utility of BCA-225 in detecting adenocarcinoma in serous effusions. Analytical And Quantitative Cytology And Histology / The International Academy Of Cytology [And] American Society Of Cytology, 22(5), 353-357.
Medical Pathology | Pathology
Department of Pathology and Laboratory Medicine, Pathology Laboratory Medicine Faculty